Summary & Overview
HCPCS C9159: Injection of Prothrombin Complex Concentrate (Balfaxar)
HCPCS Level II code C9159 represents injection of prothrombin complex concentrate (human), balfaxar, billed per international unit of factor IX activity. This code captures administration of a concentrated clotting factor product used in the management of factor IX deficiency and related acute bleeding or perioperative prophylaxis. Nationally, use of factor concentrates is clinically important due to high unit costs, specialized storage and administration needs, and implications for hospital and pharmacy billing practices.
Key payers reviewed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, and the types of benchmarks and policy issues that affect coverage and payment. The publication summarizes common billing and claim considerations, outlines areas where payer policies or edits commonly apply, and highlights clinical scenarios that drive utilization.
This resource is intended to help coding, billing, and revenue teams understand the purpose of C9159, anticipate where billing complexities arise, and locate the sections that detail reimbursement benchmarks, prior authorization trends, and documentation expectations. Data not available in the input will be noted where specific payer policies, rates, or taxonomies would normally appear.
Billing Code Overview
HCPCS Level II code C9159 describes an injection of prothrombin complex concentrate (human), balfaxar, billed per international unit of factor IX activity. This product is used to provide concentrated clotting factors for patients with deficiencies affecting factor IX, typically in acute bleeding events or perioperative management.
-
Service type: Injectable biologic therapy (factor concentrate)
-
Typical site of service: Hospital inpatient, hospital outpatient, emergency department, or ambulatory infusion center depending on clinical setting and administration requirements.
Clinical & Coding Specifications
Clinical Context
A 58-year-old male with hemophilia B (factor IX deficiency) presents to an outpatient infusion center with spontaneous joint bleeding and an elevated bleeding tendency despite recent factor IX replacement. The treating hematologist orders intravenous administration of prothrombin complex concentrate (human), balfaxar, dosed by international units of factor IX activity, for rapid correction of coagulopathy. The typical workflow includes verification of patient identity and weight, review of current medications and inhibitor status, calculation of total IU required, pharmacy preparation and reconstitution of the product, baseline vital signs and venous access placement, slow intravenous infusion per product labeling with cardiac and infusion monitoring, post-infusion observation for adverse events (thromboembolic events, hypersensitivity), documentation of lot number and IU administered, and billing using HCPCS Level II code C9159 reported per IU of factor IX activity. Typical sites of service include outpatient infusion centers, hospital outpatient departments, emergency departments when used for acute bleeding, and inpatient wards for severe bleeds or preoperative correction. Common clinical scenarios include acute hemarthrosis, severe mucosal bleeding, perioperative factor replacement for a patient with hemophilia B, or urgent reversal of coagulopathy in a patient with acquired factor IX deficiency.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |